Survey uncovers barriers to HCC surveillance
Specialty Pharmacy Continuum
Online audience: 17,545
PUBLISHED JULY 8, 2022
Managed care leaders like to keep an eye on methods for detecting cancer and intervening early to maximize clinical outcomes. In the case of hepatocellular carcinoma (HCC), a new survey-based study suggests that numerous obstacles exist on both the provider and system levels when it comes to achieving that goal via optimal surveillance. Dr. Eliza W. Beal is quoted.
For more information about CATALYST, visit http://go.osu.edu/catalyst.